Manager TitleAgeSince
President - 30/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/22 A Issuer sale

Chief Technology Officer

280,373 0.1193%
3/29/22 A Tax

Executive/Senior Manager

68,414 0.0293%
3/29/22 A Tax

Controller/Auditor

965 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.8B
+1.01%+1.74%+57.65%+128.55% 1,143B
+0.97%+5.21%+45.09%+84.46% 647B
+0.09%+0.61%+25.93%+101.95% 506B
-0.05%+1.73%+52.74%+65.27% 384B
-0.86%-6.39%+61.21%+36.64% 350B
+0.34%+1.84%+30.70%+52.69% 293B
-0.45%+1.19%+2.89%+24.92% 265B
+0.55%+2.50%+53.82%+70.71% 242B
-0.00%+3.36%+34.65%+104.10% 197B
Average +0.14%+0.85%+40.52%+74.36% 447.5B
Weighted average by Cap. +0.38%+0.71%+44.57%+87.09%
Logo Endo International plc
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116